Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 09:37:24 2024-12-10 am EST			5-day change	1st Jan Change
89.09 ^CHF	-0.32%		-3.91%	+5.31%

03:00pm	Longer-term Novartis Kisqali(R) NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer	DJ
12:15pm	NOVARTIS AG : Deutsche Bank remains Neutral	ZD

NOVARTIS AG : JP Morgan sticks Neutral

November 07, 2024 at 08:33 am EST

JP Morgan analyst Richard Vosser maintains his Neutral opinion on the stock. The target price is still set at CHF 95.

Latest news about Novartis AG

Longer-term Novartis Kisqali(R) NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer	09:00am	DJ
NOVARTIS AG : Deutsche Bank remains Neutral	06:15am	ZD
NOVARTIS AG : Jefferies remains Neutral	04:09am	ZD
Novartis AG - Special Call	Dec. 09
Novartis: positive long-term data in leukemia	Dec. 09	CF
Novartis Logs Superior Efficacy Results in Longer-term Data for Leukemia Treatment	Dec. 08	MT
Novartis Announces Positive, Long-Term Results from the Pivotal Phase III ASC4FIRST Trial with Scemblix	Dec. 08	CI
Swiss Market Index Ends Week Little Changed; Holcim Shares Down	Dec. 06	MT
Novartis Reports 'Positive' Results From Phase 3 Study of Potential Blood Disorder Therapy	Dec. 06	MT
Novartis: positive data for Fabhalta in HPN	Dec. 06	CF
Novartis' Rare Blood Disorder Drug Improves Hemoglobin Levels in Phase 3b Trial	Dec. 06	MT
New Phase IIIB data shows Novartis Fabhalta(R) improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy	Dec. 06	DJ
Novartis Announces Positive Topline Results from APPULSE-PNH, a Phase IIIB Study Evaluating the Efficacy and Safety of Two-Daily Oral Monotherapy Fabhalta	Dec. 06	CI
NOVARTIS AG : Deutsche Bank remains Neutral	Dec. 05	ZD
US Court Rejects Novartis' Appeal to Block Heart Failure Drug's Generic Version	Dec. 04	MT
Novartis cannot block generic of best-selling heart drug, US appeals court says	Dec. 04	RE
HSBC Downgrades Novartis to Reduce, Price Target is $95	Dec. 04	MT
NOVARTIS AG : JP Morgan reiterates its Neutral rating	Dec. 03	ZD
Sector Update: Health Care Stocks Slipping Late Afternoon	Dec. 02	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate	Dec. 02	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
Novartis AG, PTC Therapeutics, Inc. - M&A Call	Dec. 02

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

09:00pm - American Society of Hematology Meeting - Abstract Number - 4087

More about the company